These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The acceleration of CAR-T therapy in non-Hodgkin lymphoma. Munshi PN; Ujjani C Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551 [TBL] [Abstract][Full Text] [Related]
11. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Chow VA; Shadman M; Gopal AK Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976 [TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Levin A; Shah NN Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353 [TBL] [Abstract][Full Text] [Related]
13. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis. Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292 [TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Hunter BD; Rogalski M; Jacobson CA Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797 [No Abstract] [Full Text] [Related]
15. What CAR Will Win the CD19 Race? Quintás-Cardama A Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581 [TBL] [Abstract][Full Text] [Related]
16. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. Strati P; Neelapu SS Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158 [TBL] [Abstract][Full Text] [Related]
17. Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma. Avanzi MP; Brentjens RJ J Natl Compr Canc Netw; 2017 Nov; 15(11):1429-1437. PubMed ID: 29118234 [TBL] [Abstract][Full Text] [Related]
18. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Gauthier J; Turtle CJ Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831 [TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. Gauthier J; Yakoub-Agha I Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742 [TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma. Ghobadi A Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]